Granahan Investment Management Inc. MA Sells 3,679 Shares of Agilent Technologies, Inc. (A)
Granahan Investment Management Inc. MA trimmed its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 52.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,308 shares of the medical research company’s stock after selling 3,679 shares during the period. Granahan Investment Management Inc. MA’s holdings in Agilent Technologies were worth $212,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Dupont Capital Management Corp acquired a new position in shares of Agilent Technologies during the 3rd quarter worth about $101,000. Balentine LLC boosted its stake in shares of Agilent Technologies by 2.9% during the 2nd quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock worth $106,000 after buying an additional 50 shares during the last quarter. Sun Life Financial INC boosted its stake in shares of Agilent Technologies by 26,144.4% during the 2nd quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock worth $140,000 after buying an additional 2,353 shares during the last quarter. Acrospire Investment Management LLC boosted its stake in shares of Agilent Technologies by 92.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock worth $148,000 after buying an additional 1,200 shares during the last quarter. Finally, Parallel Advisors LLC lifted its stake in Agilent Technologies by 5.3% in the 2nd quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock valued at $157,000 after purchasing an additional 131 shares during the last quarter.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 22,481 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $70.00, for a total value of $1,573,670.00. Following the sale, the chief executive officer now owns 327,882 shares in the company, valued at $22,951,740. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Mark Doak sold 4,154 shares of the firm’s stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $67.00, for a total transaction of $278,318.00. Following the completion of the sale, the vice president now owns 68,270 shares in the company, valued at approximately $4,574,090. The disclosure for this sale can be found here. Insiders sold 117,021 shares of company stock worth $8,128,154 over the last three months.
Agilent Technologies (NYSE:A) last announced its earnings results on Monday, November 20th. The medical research company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.05. Agilent Technologies had a net margin of 15.30% and a return on equity of 16.96%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the firm earned $0.59 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. research analysts predict that Agilent Technologies, Inc. will post 2.58 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 2nd will be paid a $0.149 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.90%. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. The ex-dividend date is Friday, December 29th. Agilent Technologies’s dividend payout ratio (DPR) is 25.24%.
Several equities research analysts recently issued reports on the stock. Goldman Sachs Group reiterated a “neutral” rating and issued a $68.00 target price on shares of Agilent Technologies in a research note on Tuesday, September 26th. ValuEngine downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Cowen reiterated a “hold” rating and issued a $65.00 target price on shares of Agilent Technologies in a research note on Thursday, September 28th. Robert W. Baird reiterated a “buy” rating and issued a $72.00 target price on shares of Agilent Technologies in a research note on Friday, November 24th. Finally, Zacks Investment Research upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 target price for the company in a research note on Tuesday, October 31st. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $68.34.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Stock Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related stocks with our FREE daily email newsletter.